Skip to main content

Global United Kingdom & Ireland

Login

For Healthcare
Professionals

Home
Therapeutic areas
Products
Resources
Events
Contact

Home

Therapeutic areas

Haematology
Immunology
Nephrology
Specialty Care portfolio

Haematology

Haemophilia
Immune thrombocytopenia (ITP)
Paroxysmal Nocturnal Hemoglobinuria (PNH)

Immunology

Interleukin-1 and autoinflammatory diseases

Nephrology

C3G and IC-MPGN

C3G and IC-MPGN

Disease Pathophysiology
Patient Journey – Challenges
Disease Biomarkers
Educational Videos
Stay In Touch

Products

Alprolix (eftrenonacog alfa)
▼Altuvoct® (efanesoctocog alfa)
Aspaveli® (pegcetacoplan)
Doptelet® (avatrombopag)
Kineret® (anakinra)
Orfadin® (nitisinone)
▼Waylivra (volanesorsen)
▼Zynlonta® (loncastuximab tesirine)

Alprolix (eftrenonacog alfa)

Mode of action
Clinical trial summary
Bleed protection
Joint protection
Quality of Life
Real-world experience
Dosing
Safety profile

▼Altuvoct® (efanesoctocog alfa)

Unmet needs
About ALTUVOCT
ALTUVOCT in adults
ALTUVOCT in children

Doptelet® (avatrombopag)

About ITP
Challenge expectations
Efficacy
Dosing
Safety profile
Guidelines
Resources

Kineret® (anakinra)

Home
About Kineret
About IL-1
Still’s disease
CAPS
FMF
Safety
Resources

▼Waylivra (volanesorsen)

About FCS
Diagnosing FCS
FCS Pathogenesis
Waylivra
Mode of Action
Efficacy
Dosing Information
Waylivra Safety Profile
Waylivra Downloadable Resources

▼Zynlonta® (loncastuximab tesirine)

Home
Efficacy
2-year follow up data
Post-CAR-T: Real-world evidence (RWE)
Dosing and administration
Overall Safety Profile
Resources

Efficacy

Speed of onset and sustainability of response
Consistency of response
Effectiveness following switch from other TPO-RA

Resources

Case studies
EVOLVE meeting hightlights
Podcast series for Ireland
Podcast series for UK

Efficacy

APPROACH Study - Study Design & Baseline Characteristics
APPROACH Study - Primary Endpoint & Results

Efficacy

Post-CAR-T: LOTIS-2 sub-analysis

Overall Safety Profile

Non-haematological TEAEs
Haematological & laboratory TEAEs
Special warnings and precautions for use
Myelosuppression, cytopenias management and dose modifications for AEs

Resources

Expert opinion videos
Real World Experience case studies
BSH 2024 highlights
Podcasts

Resources

Events

Contact

Global United Kingdom & Ireland

Home
Therapeutic areas
Products
Resources
Events
Contact

Haematology
Immunology
Nephrology
Specialty Care portfolio

Haemophilia
Immune thrombocytopenia (ITP)
Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interleukin-1 and autoinflammatory diseases

C3G and IC-MPGN

Disease Pathophysiology
Patient Journey – Challenges
Disease Biomarkers
Educational Videos
Stay In Touch

Video Series: Pathophysiology with Prof Matthew Pickering
Video Series: Paediatric nephrologist’s perspectives with Dr Dean Wallace
Video Series: Expert nephrologist’s perspectives with Dr Edwin Wong

Alprolix (eftrenonacog alfa)
▼Altuvoct® (efanesoctocog alfa)
Aspaveli® (pegcetacoplan)
Doptelet® (avatrombopag)
Kineret® (anakinra)
Orfadin® (nitisinone)
▼Waylivra (volanesorsen)
▼Zynlonta® (loncastuximab tesirine)

Mode of action
Clinical trial summary
Bleed protection
Joint protection
Quality of Life
Real-world experience
Dosing
Safety profile

Unmet needs
About ALTUVOCT
ALTUVOCT in adults
ALTUVOCT in children

About ITP
Challenge expectations
Efficacy
Dosing
Safety profile
Guidelines
Resources

Speed of onset and sustainability of response
Consistency of response
Effectiveness following switch from other TPO-RA

Case studies
EVOLVE meeting hightlights
Podcast series for Ireland
Podcast series for UK

Home
About Kineret
About IL-1
Still’s disease
CAPS
FMF
Safety
Resources

About FCS
Diagnosing FCS
FCS Pathogenesis
Waylivra
Mode of Action
Efficacy
Dosing Information
Waylivra Safety Profile
Waylivra Downloadable Resources

APPROACH Study - Study Design & Baseline Characteristics
APPROACH Study - Primary Endpoint & Results

Home
Efficacy
2-year follow up data
Post-CAR-T: Real-world evidence (RWE)
Dosing and administration
Overall Safety Profile
Resources

Post-CAR-T: LOTIS-2 sub-analysis

Non-haematological TEAEs
Haematological & laboratory TEAEs
Special warnings and precautions for use
Myelosuppression, cytopenias management and dose modifications for AEs

Expert opinion videos
Real World Experience case studies
BSH 2024 highlights
Podcasts

Login

Home
Alprolix PI UK IE

Prescribing Information

Download file (182 KB)

PP-26168 Jan, 2025

The information on this website is intended for Healthcare Professionals (HCPs) only.
© 2026 Swedish Orphan Biovitrum AB (publ).

Date of last revision of site: August 2026
NP-49604

Privacy Policy Terms of use Cookie policy Cookies Settings

www.sobi.com/uk/en

Swedish Orphan Biovitrum Ltd
Suite 2, Riverside 3, Granta Park, Great Abington, Cambridgeshire CB21 6AD
Reg.No. 556038-9321

[email protected]